Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Immune checkpoint inhibitors
6 evidence topics · 4 sources
FDA-approved tumor-agnostic indications
MSI-H or dMMR solid tumors: objective response in prostate cancer
| Tumor type | Patients | Objective response, n (%) | 95% CI | Duration of response, months |
|---|---|---|---|---|
| Prostate cancer | “8” | “1 (13%)” | “(0%, 53%)” | “24.5+” |
Prevalence of MSI-H or dMMR prostate cancer and response to PD-1 or PD-L1 blockade
“Among the 1033 patients who had adequate tumor quality for MSIsensor analysis (mean [SD] age, 65.6 [9.3] years), 32 (3.1%) had MSI-H/dMMR prostate cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven patients with MSI-H/dMMR castration-resistant prostate cancer received anti–PD-1/PD-L1 therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six of these (54.5%) had a greater than 50% decline in prostate-specific antigen levels, 4 of whom had radiographic responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab monotherapy in biomarker-unselected disease after docetaxel and endocrine therapy
“Cohorts 1 and 2 enrolled patients with RECIST-measurable PD-L1–positive and PD-L1–negative disease, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Objective response rate was 5% (95% CI, 2% to 11%) in cohort 1 and 3% (95% CI, < 1% to 11%) in cohort 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 9.5 months in cohort 1, 7.9 months in cohort 2, and 14.1 months in cohort 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote